Microbot Medical Reports More Than 100% Revenue and Customer Growth in Second Quarter of 2026
Microbot Medical, a medical technology company specializing in robotic systems for minimally invasive vascular procedures, has reported more than 100% growth in both revenue and new customer acquisition during the second quarter of 2026 compared with the first quarter of the year. The strong financial and commercial performance reflects growing adoption of the company’s LIBERTY® Endovascular Robotic System, following its full commercial launch in the United States earlier this year.
The company attributes the quarter’s momentum to increasing demand from major healthcare systems, expanding clinical utilization of its robotic platform, a growing national sales network, new partnerships serving federal healthcare organizations, and continued international expansion. Together, these developments represent important milestones in Microbot Medical’s strategy to establish the LIBERTY System as a next-generation robotic solution for endovascular procedures.
The company also announced progress in expanding manufacturing capacity and securing international regulatory approvals, positioning the business to support anticipated long-term growth as adoption continues to accelerate.
Strong Commercial Performance Following Full Market Release
Microbot Medical officially initiated the Full Market Release (FMR) of the LIBERTY Endovascular Robotic System on April 13, 2026, marking the transition from limited commercial availability to broader deployment across the United States.
The second quarter represented the first full reporting period following this expanded launch.
According to the company, both revenue and the number of new customers more than doubled compared with the first quarter of 2026.
The growth reflects increasing confidence among hospitals and health systems seeking advanced robotic technologies capable of improving precision, workflow efficiency, and physician ergonomics during minimally invasive vascular procedures.
Commercial adoption accelerated across several important regional healthcare markets, providing a broader customer base for continued expansion.
Growing Adoption Across Leading Health Systems
During the second quarter, several prominent healthcare organizations adopted the LIBERTY robotic platform.
New customer installations occurred within major health systems located in:
- Massachusetts
- North Carolina
- Michigan
- Pennsylvania
These additions represent an important step in expanding the company’s national presence.
Large integrated health systems often serve as influential early adopters of innovative medical technologies because they perform high procedure volumes, maintain specialized vascular programs, and frequently participate in clinical innovation initiatives.
Successful implementation within these institutions may also increase awareness of the technology among physicians practicing at affiliated hospitals and outpatient centers.
As clinical experience grows, broader adoption may follow throughout additional facilities within each health system.
Transition from Limited to Full Commercialization
Before entering full commercial release, the LIBERTY System underwent a Limited Market Release (LMR).
Limited market releases allow medical device manufacturers to introduce new technologies to selected clinical sites while gathering real-world experience before broader commercialization.
This approach enables companies to:
- Evaluate clinical workflows
- Collect physician feedback
- Optimize training programs
- Refine customer support
- Validate operational readiness
- Improve manufacturing processes
Microbot Medical indicated that insights gained during the LMR helped support a successful nationwide commercial expansion beginning in April.
The transition has resulted in increasing customer acquisition and stronger utilization across existing installations.
Procedure Volume Continues to Increase
Beyond acquiring new customers, the company reported meaningful growth in procedure volume at hospitals that had already adopted the LIBERTY System during the Limited Market Release.
Existing users performed more robotic-assisted procedures during the second quarter than in the previous reporting period.
According to the company, higher procedure volume resulted from several factors:
- Expansion into additional clinical sites
- Greater physician adoption
- Increased user familiarity
- Broader integration into routine clinical practice
Growing utilization within current customer accounts represents an important commercial indicator because it demonstrates continued engagement after initial installation.
Increasing procedure frequency may also contribute to recurring revenue opportunities associated with system usage and future service agreements.
Expanding Clinical Utilization
As physicians become increasingly familiar with robotic-assisted endovascular procedures, hospitals often expand use across additional clinicians and procedural settings.
Microbot Medical noted that more healthcare professionals are transitioning to the LIBERTY platform as confidence grows in its clinical capabilities.
This broader physician adoption may help maximize return on investment for healthcare organizations while encouraging continued procedural growth.
Site expansion also enables health systems to make robotic technology available across multiple departments or affiliated facilities, increasing access for patients requiring minimally invasive vascular interventions.
These developments contribute to stronger long-term commercial performance beyond initial equipment sales.
Understanding Endovascular Robotics
Endovascular procedures involve treating diseases affecting blood vessels using minimally invasive techniques.
Rather than performing open surgery, physicians guide catheters, guidewires, balloons, stents, and other specialized devices through blood vessels using small access points.
These procedures are commonly performed to diagnose or treat conditions affecting arteries and veins throughout the body.
Robotic systems designed for endovascular interventions assist physicians by enabling precise remote manipulation of interventional devices.
Potential advantages may include:
- Improved procedural precision
- Enhanced catheter control
- Greater physician ergonomics
- Reduced radiation exposure
- Increased procedural consistency
- Improved workflow efficiency
As minimally invasive therapies continue expanding across cardiovascular and peripheral vascular medicine, robotic technologies are expected to play an increasingly important role.
About the LIBERTY Endovascular Robotic System
The LIBERTY Endovascular Robotic System represents Microbot Medical’s flagship technology platform.
Unlike larger robotic systems requiring substantial operating room infrastructure, LIBERTY has been designed with portability and workflow flexibility in mind.
The system enables physicians to remotely control endovascular devices during minimally invasive procedures while remaining outside the immediate radiation field.
By allowing clinicians to operate from a protected workstation, robotic assistance may reduce cumulative radiation exposure and physical strain associated with lengthy vascular procedures.
The technology also supports precise device navigation throughout complex vascular anatomy.
Expanding Sales Infrastructure
Growing commercial demand prompted Microbot Medical to significantly increase its sales organization during the second quarter.
The company expanded its U.S. sales footprint from:
- Four territories
to - Eight territories
Management also reported plans to continue expanding nationwide.
By the end of 2026, the company expects to operate across approximately 12 sales territories throughout the United States.
Expanding commercial infrastructure allows the organization to:
- Increase customer engagement
- Support physician education
- Accelerate new installations
- Improve clinical support
- Strengthen customer relationships
A larger sales organization positions the company to capitalize on increasing interest from hospitals considering robotic vascular technologies.
Partnership Serving Federal Healthcare Systems
One of the quarter’s notable developments involved Microbot Medical’s partnership with Lovell Government Services Inc.
Through this agreement, the company will pursue opportunities within several major federal healthcare systems.
Potential customers include:
- Veterans Health Administration (VHA)
- Military Health System (MHS)
- Indian Health Service (IHS)
These organizations collectively provide healthcare services to millions of patients throughout the United States.
Entering the federal healthcare market represents an important commercial opportunity because these systems often manage substantial procedural volumes while maintaining advanced cardiovascular and vascular care programs.
Participation within federal procurement channels may also expand long-term market visibility.
Serving Veterans and Military Healthcare
The Veterans Health Administration represents one of the largest integrated healthcare systems in the United States.
It operates numerous medical centers, outpatient clinics, and specialized treatment facilities serving military veterans nationwide.
Similarly, the Military Health System provides healthcare services for active-duty military personnel, retirees, and eligible family members.
The Indian Health Service delivers healthcare to eligible American Indian and Alaska Native populations through hospitals, clinics, and tribal healthcare facilities.
Access to these healthcare networks may significantly broaden the potential reach of the LIBERTY robotic platform.
International Expansion Begins
Microbot Medical also achieved an important international regulatory milestone during the quarter.
The company received marketing clearance for the LIBERTY System from the AMAR Division of the Israeli Ministry of Health.
This approval makes Israel the first country outside the United States to authorize commercial marketing of the robotic platform.
International regulatory clearance represents an important step toward global commercialization.
Successful market entry in Israel may provide valuable clinical experience while supporting future regulatory submissions in additional international markets.
Expanding geographically also diversifies commercial opportunities beyond the domestic U.S. market.
Building Manufacturing Capacity
As commercial demand continues increasing, manufacturing capacity becomes increasingly important.
To support anticipated growth, Microbot Medical recently entered into an agreement establishing a second manufacturing site.
Expanding production capabilities provides several strategic advantages.
Additional manufacturing capacity can:
- Support increasing customer demand
- Reduce production bottlenecks
- Improve supply chain resilience
- Enhance operational flexibility
- Support international expansion
- Enable larger production volumes
Multiple manufacturing facilities also reduce operational risk by providing greater redundancy within production operations.
Positioning for Long-Term Growth
Management indicated that expanding manufacturing capacity may also contribute to improved financial performance over time.
As production volumes increase, companies frequently realize operational efficiencies associated with larger-scale manufacturing.
Potential benefits include:
- Lower production costs
- Improved operational efficiency
- Better supply management
- Increased manufacturing flexibility
- Stronger profit margins
These efficiencies may become increasingly important as commercial adoption accelerates both domestically and internationally.
Growing Interest in Robotic-Assisted Procedures
Robotic technologies continue gaining momentum across numerous medical specialties.
Initially popularized within minimally invasive surgery, robotics now play expanding roles in:
- Cardiovascular interventions
- Endovascular procedures
- Neurosurgery
- Orthopedics
- Urology
- General surgery
Healthcare providers increasingly seek technologies capable of improving procedural precision while enhancing physician comfort and workflow efficiency.
Endovascular robotics remains one of the fastest-evolving segments within medical technology as manufacturers develop increasingly sophisticated systems for minimally invasive vascular interventions.
Microbot Medical’s second-quarter results highlight growing commercial momentum following the full market release of the LIBERTY Endovascular Robotic System. With more than 100% growth in revenue and customer acquisition, rising procedure volumes among existing users, expanded sales operations, and entry into major federal healthcare systems, the company continues to strengthen its position within the rapidly evolving field of robotic-assisted endovascular medicine.
Additional milestones—including regulatory approval in Israel and the establishment of a second manufacturing facility—further support the company’s long-term growth strategy. As hospitals increasingly adopt robotic technologies to improve procedural precision, workflow efficiency, and patient care, Microbot Medical appears well positioned to expand both its domestic and international presence while advancing the broader adoption of robotic solutions for minimally invasive vascular interventions.
Source link: https://ir.microbotmedical.com/
